Breaking News Instant updates and real-time market news.

PEP

PepsiCo

$110.83

-0.98 (-0.88%)

, PYX

Pyxus

$23.15

0.25 (1.09%)

09:11
10/02/18
10/02
09:11
10/02/18
09:11

Fly Intel: Pre-market Movers

HIGHER: Pyxus International (PYX), up 4% after subsidiary Goldleaf Pharm received a cannabis cultivation license... Papa John's (PZZA), up 4% after Legion Partners Asset Management reported about a 5.5% stake in the company... Verastem (VSTM), up 3% after duvelisib approval by the FDA.... General Electric (GE), up 2.5% after Emerson (EMR) announced it has agreed to acquire Intelligent Platforms, a division of GE. DOWN AFTER EARNINGS: Pepsi (PEP), down 1.6%... Stitch Fix (SFIX), down 21%. LOWER: MongoDB (MDB), down 3.6% after Nomura Instinet Christopher Eberle downgraded the stock to Reduce from Neutral, contending that the company's current market value reflects "extreme valuation."... Veoneer (VNE), down 4% after UBS analyst David Lesne downgraded the stock to Sell from Neutral with a $44 price target, citing high valuation and "unattractive" risk-reward... U.S. Steel (X), down 2.5% after Deutsche Bank analyst Chris Terry downgraded the stock to Hold as he has become more cautious on steel stocks.

PEP

PepsiCo

$110.83

-0.98 (-0.88%)

PYX

Pyxus

$23.15

0.25 (1.09%)

SFIX

Stitch Fix

$44.70

0.9 (2.05%)

PZZA

Papa John's

$49.28

-2.04 (-3.98%)

VSTM

Verastem

$6.52

-0.745 (-10.26%)

GE

General Electric

$12.09

0.8 (7.09%)

MDB

MongoDB

$78.86

-2.65 (-3.25%)

VNE

Veoneer

$55.53

0.5 (0.91%)

X

U.S. Steel

$30.24

-0.24 (-0.79%)

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 04

    Oct

  • 05

    Oct

  • 05

    Oct

  • 29

    Oct

  • 29

    Oct

  • 02

    Nov

  • 13

    Nov

  • 27

    Nov

PEP PepsiCo
$110.83

-0.98 (-0.88%)

08/14/18
EVER
08/14/18
NO CHANGE
EVER
BodyArmor stake positive for Coca-Cola, negative for Pepsi, says Evercore
Evercore ISI analyst Robert Ottenstein views Coca-Cola's stake in BodyArmor as a "clear positive" for the company and a "clear negative" for both PepsiCo (PEP) and Keurig Dr Pepper (KDP). Pepsi's Gatorade product is most at risk with Coca-Cola taking a stake in BodyArmor, and Keurig Dr Pepper "losses distribution of the product and any path to ownership it might have enjoyed," Ottenstein tells investors in a research note.
07/24/18
RHCO
07/24/18
NO CHANGE
Target $110
RHCO
Hold
PepsiCo price target raised to $110 from $105 at SunTrust
SunTrust analyst William Chappell raised his price target on PepsiCo to $110 to account for gains related to the impact of refranchising transactions, which he expects to support the company's high-single-digit EPS growth trend going forward. The analyst also keeps his Hold rating on PepsiCo as the stock is "fairly valued", with the company's Beverage business trading in line with peers and the Food business trading at the high end of its large-cap snack food peer range.
07/23/18
JEFF
07/23/18
NO CHANGE
Target $107
JEFF
Hold
Jefferies sees risk of near-term downside in PepsiCo shares
Jefferies analyst Kevin Grundy sees potential near-term downside in shares of PepsiCo. Despite fundamental challenges and weak earnings quality, PepsiCo's "relative multiple remains elevated," Grundy tells investors in a research note. The analyst is "negatively biased" toward PepsiCo and reiterates a Hold rating on the shares with a $107 price target.
09/13/18
GUGG
09/13/18
INITIATION
GUGG
Neutral
PepsiCo initiated with a Neutral at Guggenheim
PYX Pyxus
$23.15

0.25 (1.09%)

SFIX Stitch Fix
$44.70

0.9 (2.05%)

09/20/18
09/20/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BAIRD UPGRADES CATERPILLAR TO OUTPERFORM: Baird analyst Mig Dobre upgraded Caterpillar (CAT) to Outperform from Neutral. The analyst believes demand growth should continue into 2019. While some markets like China are close to peak, most of its demand is still at or below mid-cycle levels, said Dobre, who raised his price target to $191 from $155 on Caterpillar shares. Caterpiller is up 1.5% in late morning trading. PIPER CUTS STITCH FIX TO NEUTRAL: Piper Jaffray analyst Erinn Murphy downgraded Stitch Fix (SFIX) to Neutral while raising her price target for the shares to $43 from $29. The analyst cited valuation for the downgrade. With shares nearing $50, market expectations do not provide any margin of error, Murphy said. She believes the "smallest hint" of pressure could be a significant negative catalyst for the stock. Further, the analyst notes that Amazon's (AMZN) Prime Wardrobe is now advertising in key NFL slots and that the company is testing a personalized recommendation service for certain categories. In late morning trading, Stitch Fix is lower by over 13%. COWEN CUTS SKECHERS TO MARKET PERFORM: Cowen analyst John Kernan downgraded Skechers (SKX) to Market Perform from Outperform citing growing inventory levels, particularly as foreign exchange headwinds in key markets build. He also believes consensus forecasts for operating expansion are too optimistic. Kernan lowered his price target to $28 from $32 on Skechers shares, which are down 4.7% in late morning trading. JPMORGAN CUTS GE'S PRICE TARGET: JPMorgan analyst Stephen Tusa lowered his price target for General Electric (GE) to $10 from $11 and kept an Underweight rating on the shares. The impact on "asset value" from a failure at GE's U.S. H-frame launch customer, while tough to estimate, represents a negative development for a company that has little wiggle room for more "shoes to drop," Tusa said. MORGAN STANLEY POSITIVE ON APPLE IPHONE DUAL-SIM ADDITION: In EMEA and Asia, smartphones with dual-SIM capabilities have become the status quo, noted Morgan Stanley analyst Katy Huberty, who believes that Apple adding dual-SIM to the new iPhones is an underappreciated feature with the potential to drive upside to shipments in FY19. Huberty kept an Overweight rating and $247 price target on Apple shares.
09/25/18
JPMS
09/25/18
NO CHANGE
Target $36
JPMS
Neutral
Stitch Fix price target raised to $36 from $26 at JPMorgan
JPMorgan analyst Doug Anmuth raised his price target for Stitch Fix to $36 but keeps a Neutral rating on the shares. The stock is up 110% since the company's fiscal Q3 earnings report on June 7, which the analyst attributes to a widely held view that management's Q4 guidance is conservative and consensus fiscal 2019 estimates are too low. He agrees that the Q4 guidance has upside potential. However, while Anmuth remains confident in Stitch Fix's market opportunity, he like to see another quarter or two of 25%-plus revenue growth and better margin visibility before getting more constructive on the name.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $31
PIPR
Overweight
Stitch Fix price target lowered to $31 from $43 at Piper Jaffray
Piper Jaffray analyst Erinn Murphy lowered her price target for Stitch Fix to $31 saying the outlook for Q1 suggests the company's core growth is moderating. The analyst remains on the sidelines with respect to the shares and keeps a Neutral rating on Stitch Fix.
10/02/18
STFL
10/02/18
NO CHANGE
Target $30
STFL
Hold
Stitch Fix price target raised to $30 after 'mixed' Q4 at Stifel
Stifel analyst Scott Devitt said Stitch Fix reported "mixed" Q4 results with adjusted EBITDA above consensus and revenue growth modestly below analysts' expectations. While he supports management's selected areas of investment, Devitt believe the stocks' current valuation reflects the company's attractive growth opportunities. He raised his price target on Stitch Fix shares to $30 from $26 following the earnings report and maintains a Hold rating on the stock.
PZZA Papa John's
$49.28

-2.04 (-3.98%)

08/27/18
08/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. First Majestic (AG) upgraded to Outperform from Market Perform at BMO Capital with analyst Ryan Thompson citing his expectations of gross margin improvement following the shutdown of the high-cost La Guitarra mine and the integration of the high-margin San Dimas mine. 2. Papa John's (PZZA) upgraded to Buy from Neutral at Kalinowski with analyst Mark Kalinowski saying he believes the reported hiring of Bank of America and Lazard increases the odds of a favorable outcome over the next 12 months, including the possibility of an acquisition. 3. Portola Pharmaceuticals (PTLA) upgraded to Neutral from Underperform at Credit Suisse with analyst Vamil Divan citing Johnson & Johnson (JNJ) and Bayer's (BAYRY) presentation of disappointing data for Xarelto in the acute medically ill population at ESC. 4. Bancolombia (CIB) upgraded to Neutral from Sell at Citi. 5. AK Steel (AKS) and Steel Dynamics (STLD) were upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/07/18
STFL
09/07/18
NO CHANGE
Target $38
STFL
Hold
Papa John's store closure risk may be under-appreciated, says Stifel
Stifel analyst Chris O'Cull believes Papa John's domestic same-store sales remain challenged and he is surprised the company's aggressive promotions over the past several weeks have not slowed the declines. If the trend persists, it could lead to accelerating store closures in the next six months, which not only would impact royalty revenue but represents a risk to commissary profits that the Street may be under-appreciating, O'Cull tells investors. He maintains a Hold rating on Papa John's shares with a $38 price target.
09/27/18
JEFF
09/27/18
NO CHANGE
Target $58
JEFF
Buy
Jefferies continues to see upside potential in shares of Papa John's
Jefferies analyst Alexander Slagle continues to believe Q3 will represent the worst in terms of fundamentals for Papa John's (PZZA) and that "ultimate upside potential outweighs downside." The analyst recommends looking past fear of near-term trends and buying shares of Papa John's. An analysis of potential refranchising and leveraged buyout scenarios suggest there continues to be opportunities for value creation, Slagle tells investors in a research note. The analyst says that even without a buyout, there is a three-to-five year path to recovery that could return Papa John's to its normalized earnings/EBITDA levels and growth rate, potentially driving $4.00-plus of earnings per share by 2020. Slagle adds that based on this week's acquisition of Sonic (SONC) by Inspire Brands, Papa John's would be worth $63.50 per share in a buyout. He keeps a Buy rating on Papa John's with a $58 price target.
08/27/18
08/27/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. MORGAN STANLEY DOUBLE DOWNGRADES U.S. STEEL: Morgan Stanley analyst Piyush Sood double downgraded U.S. Steel (X) to Underweight from Overweight as he notes that steel prices are falling and he believes the recent price peak is "firmly behind" the market. Sood lowered his price target on U.S. Steel shares to $30 from $44. He prefers AK Steel (AKS), which he upgraded to Overweight from Equal Weight citing its good free cash flow prospects, and also prefers Steel Dynamics (STLD), which he also upgraded to Overweight from Equal Weight. PAPA JOHN'S UPGRADED TO BUY: Kalinowski Equity Research's Mark Kalinowski upgraded Papa John's (PZZA) to Buy from Neutral as he believes the reported hiring of Bank of America and Lazard increases the odds of a favorable outcome over the next 12 months, including the possibility of an acquisition. He noted that CNBC reports the company "isn't currently exploring a sale," but he believes a sale makes a lot of sense. BLOOM ENERGY CUT TO UNDERPERFORM: Credit Suisse analyst Michael Weinstein downgraded Bloom Energy (BE) to Underperform from Neutral, with a $24 price target on the stock, on valuation. While the analyst acknowledged the disruptive potential of Bloom Energy's technology, the stock is now trading at a premium. Although the company has shown impressive success so far, much work remains to be done to continue lowering costs and deliver next generation improvements, he contended. WEDBUSH CUTS CHIPOTLE TO UNDERPERFORM: Wedbush analyst Nick Setyan downgraded Chipotle Mexican Grill (CMG) to Underperform from Neutral and lowered his price target for the shares to $445 from $450. Setyan sees increased risk to Chipotle's near-term same-store-sales growth and margin expectations, and continues to see risk to margin expectations through 2020. Quarter-to-date checks suggest risk to the current Q3 consensus same-store-sales growth expectation, Setyan said. Further, the analyst believes that while theoretical drivers towards 2019 same-store-sales growth expectations exist, the risks are underappreciated.
VSTM Verastem
$6.52

-0.745 (-10.26%)

08/09/18
RAJA
08/09/18
NO CHANGE
RAJA
Verastem price target raised to $12 from $7 at Raymond James
07/13/18
BTIG
07/13/18
INITIATION
Target $17
BTIG
Buy
Verastem initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Verastem with a Buy rating and a price target of $17. The analyst cites the potential of the company's pipeline - namely the "late-stage, first-in-class molecule Duvelisib that selectively targets the delta and gamma phosphoinositide 3-kinase isoforms, central signaling pathways in cancer cell proliferation and survival". Hazlett adds that its " successful Phase 3 DUO trial in relapsed/refractory chronic lymphocytic leukemia, combined with solid data from the Phase 2 DYNAMO study in refractory follicular lymphoma, have led to Duvelisib receiving a Priority Review from FDA" with an upcoming Oct 5th PDUFA, as well as a licensing deal. The analyst models potential U.S. peak revenue over $500M and international revenue over $350M in Duvelisib's initial indications.
07/09/18
OPCO
07/09/18
NO CHANGE
Target $16
OPCO
Outperform
Verastem price target raised to $16 from $11 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Verastem to $16 from $11 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
09/25/18
HCWC
09/25/18
NO CHANGE
Target $15
HCWC
Buy
Verastem price target raised to $15 from $10 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Verastem to $15 after the FDA approved the company's lead product, Copiktra , for the treatment of third-line chronic lympocytic leukemia, small lympocytic leukemia, and follicular lymphoma. Not unexpectedly, the FDA has included a boxed warning highlighting the increased risk of serious infections, diarrhea, and colitis with Copiktra, the analyst adds. He expects Copiktra to generate revenues of $178M for these three indications by 2025 and keeps a Buy rating on Verastem.
GE General Electric
$12.09

0.8 (7.09%)

10/02/18
SBSH
10/02/18
NO CHANGE
SBSH
Buy
GE management change bigger than $23B impairment, says Citi
Yesterday's announcement of Larry Culp being named Chairman and CEO is a "new beginning" for General Electric, Citi analyst Andrew Kaplowitz tells investors in a research note. The analyst says that while the Power business is "dramatically worse" than he thought, a "proven outside leader" can immediately accelerate the pace of change and execution. Management change is bigger and more forward looking than the $23B non-cash impairment the company will take on its Power business, Kaplowitz contends. The analyst keeps a Buy rating on General Electric.
10/02/18
RBCM
10/02/18
UPGRADE
Target $15
RBCM
Outperform
General Electric upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Deane Dray upgraded General Electric to Outperform and raised his price target for the shares to $15 from $13. The analyst believes a floor has been put in the shares following news of Larry Culp being named Chairman and CEO.
10/01/18
JPMS
10/01/18
NO CHANGE
JPMS
GE 'negative surprise' raises questions about serious issues, says JPMorgan
JPMorgan analyst Stephen Tusa said the timing and format of GE's (GE) CEO change announcement is a negative surprise that raises questions as to whether there are "serious issues at play." While the selection of ex-Danaher (DHR) CEO Larry Culp is a positive for investor confidence and the change brings the company a step closer to a real reset, the details on how potentially bad things actually are have not been shared and Tusa sees a dividend cut and potential equity raise as likely, he tells investors. The analyst maintains a $10 price target and Underweight rating on GE shares, which are up 97c, or 8.5%, to $12.26 in afternoon trading.
10/02/18
WOLF
10/02/18
UPGRADE
WOLF
Outperform
General Electric upgraded to Outperform from Peer Perform at Wolfe Research
MDB MongoDB
$78.86

-2.65 (-3.25%)

10/02/18
NOMU
10/02/18
DOWNGRADE
Target $63
NOMU
Reduce
Nomura downgrades MongoDB to Reduce on 'extreme valuation'
Nomura Instinet Christopher Eberle downgraded MongoDB (MDB) to Reduce from Neutral while raising his price target for the shares to $63 from $43. The stock closed yesterday at $78.86. The company's current market value reflects "extreme valuation," Eberle tells investors in a research note. MongoDB has a "compelling" multi-year, if not multi-decade, opportunity, but it faces "intense competition and deep-pocketed incumbency that won't die easily," the analyst contends. He points out that in the last year alone, Microsoft's (MSFT) Cosmos DB grew from zero to $100M revenue. Eberle believes the current market price of MongoDB assumes no risks.
10/02/18
NOMU
10/02/18
DOWNGRADE
NOMU
Reduce
MongoDB downgraded to Reduce from Neutral at Nomura Instinet
09/17/18
LEHM
09/17/18
NO CHANGE
Target $105
LEHM
Overweight
MongoDB price target raised to $105 from $79 at Barclays
Barclays analyst Raimo Lenschow raised his price target for MongoDB to $105 after basing his valuation on a long-term model. MongoDB looks well positioned as the leading vendor in the NoSQL market, which is estimated to grow at more than 30% annually through 2023, Lenschow tells investors in a research note. The analyst keeps an Overweight rating on the shares.
09/12/18
BTIG
09/12/18
INITIATION
BTIG
Neutral
MongoDB initiated with a Neutral at BTIG
VNE Veoneer
$55.53

0.5 (0.91%)

09/19/18
09/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aerpio Pharmaceuticals (ARPO) initiated with a Buy at Guggenheim. 2. Vocera (VCRA) initiated with a Buy at Jefferies. 3. Veoneer (VNE) initiated with a Neutral at Buckingham. 4. Virtu Financial (VIRT) initiated with a Neutral at Compass Point. 5. Internap (INAP) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/18
UBSW
10/02/18
DOWNGRADE
UBSW
Sell
Veoneer downgraded to Sell from Neutral at UBS
09/27/18
RBCM
09/27/18
NO CHANGE
Target $50
RBCM
Sector Perform
Veoneer price target raised to $50 from $42 at RBC Capital
RBC Capital analyst Joseph Spak raised his price target on Veoneer to $50 after meeting with its Investor Relations VP Ray Pekar. The analyst says the discussion indicated that investors are looking beyond the near-term industry headwinds, such as softer China demand and lower passenger car production in North America, that would likely impact the second half of the year. Instead, Spak contends that the investment story on Veoneer is more about "order growth and future revenue acceleration" beyond 2020. The analyst keeps his Sector Perform rating on Veoneer, forecasting its 2017-2025 annualized sales growth around 12%, even though he sees the acceleration as "back-end weighted" based on the current progression of its active safety product portfolio.
10/02/18
UBSW
10/02/18
DOWNGRADE
Target $44
UBSW
Sell
Veoneer downgraded to Sell at UBS on valuation, risk-reward
UBS analyst David Lesne downgraded Veoneer to Sell from Neutral with a $44 price target, citing high valuation and "unattractive" risk-reward. In a research note to investors, Lesne says with shares up since the spinoff, he believes it is already pricing in a potential raise of the 2020 targets and "overly optimistic" sales and profitability outlooks in the long run. He thinks this is "unjustified" due to lack of evidence that organic sales growth is at a turning point in the near-term, adding that Veoneer is "unlikely" to become a leader in Autonomous Vehicles given competition from tech players and risk of OEM software insourcing and hardware commoditization. In the medium-term, Lesne does not see higher sales translating into improved profitability.
X U.S. Steel
$30.24

-0.24 (-0.79%)

09/04/18
UBSW
09/04/18
NO CHANGE
UBSW
UBS still cautious on steel sector, but says caution already priced into stocks
UBS analyst Andreas Bokkenheuser said he remains cautious on the steel sector and said his research shows there is more imports on flat steel than rolled. That is more negative for US Steel (X) and AK Steel (AKS) than Nucor (NUE) and Steel Dynamics (STLD). He also believes the shares are pricing in a steel price correction already, so he expects the equities to outperform the physical prices.
09/27/18
LBOW
09/27/18
NO CHANGE
Target $49
LBOW
Buy
U.S. Steel estimates lowered on OCTG survey weakness at Longbow
Longbow analyst Chris Olin's latest sruvey of energy metal distributors and traders showed a deceleration in shipment growth reported by OCTG. Olin believes slowing end market demand growth, excess distribution inventories and modestly lower trending spot prices could ultimately limit Tubular Segment upside over the next 2-3 quarters, and when combined with negative momentum in carbon steel, puts $650M EBIT guidance at risk. The analyst lowered U.S. Steel's 2018 earnings forecast to $5.71 from $5.78, but maintains a Buy rating saying the company is positioned for continued earnings growth in 2019 as sheet/tube contracts stabilize at higher levels and US production moves towards 11-12M tons.
10/02/18
DBAB
10/02/18
DOWNGRADE
Target $35
DBAB
Hold
U.S. Steel downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded U.S. Steel to Hold and lowered his price target for the shares to $35 from $47. The analyst says he's becoming more cautious on steel stocks.
10/02/18
DBAB
10/02/18
NO CHANGE
DBAB
Deutsche downgrades Reliance, U.S. Steel on more cautious steel stance
To reflect a more cautious view on steel stocks, Deutsche Bank analyst Chris Terry downgraded both Reliance Steel (RS) and U.S. Steel (X) to Hold from Buy. The analyst says his view on the sector is "moderating post peak pricing." Most positive data points and catalysts have now largely played out, Terry tells investors in a research note. The analyst, however, keeps Buy ratings on Commercial Metals (CMC), Nucor (NUE) and Steel Dynamics (STLD) citing more favorable risk/reward profiles.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
Morgan Stanley China hardware analyst to hold analyst/industry conference call »

China Hardware Tech…

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

CFG

Citizens Financial

$36.36

1.44 (4.12%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:33
10/20/18
10/20
12:33
10/20/18
12:33
Periodicals
Citizens Financial stock worth buying, Barron's says »

Citizens Financial (CFG)…

CFG

Citizens Financial

$36.36

1.44 (4.12%)

AAPL

Apple

$219.28

3.3 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.95

-1 (-0.65%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:26
10/20/18
10/20
12:26
10/20/18
12:26
Periodicals
Netflix emerged as winner in new way to rank big tech stocks risk, Barron's says »

A year ago,…

FB

Facebook

$153.95

-1 (-0.65%)

AAPL

Apple

$219.28

3.3 (1.53%)

AMZN

Amazon.com

$1,763.91

-7.54 (-0.43%)

NFLX

Netflix

$332.69

-14.02 (-4.04%)

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

DIS

Disney

$118.81

2.55 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 03

    Mar

BABA

Alibaba

$142.90

1.1 (0.78%)

, TCEHY

Tencent

$0.00

(0.00%)

12:17
10/20/18
10/20
12:17
10/20/18
12:17
Periodicals
Chinese internet giants down, not out, Barron's says »

Alibaba (BABA), Tencent…

BABA

Alibaba

$142.90

1.1 (0.78%)

TCEHY

Tencent

$0.00

(0.00%)

BIDU

Baidu

$191.93

0.1 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 02

    Nov

BLK

BlackRock

$401.61

1.74 (0.44%)

, IVZ

Invesco

$22.00

0.74 (3.48%)

12:13
10/20/18
10/20
12:13
10/20/18
12:13
Periodicals
Fund companies sued by own employees over pricey 401k plans, Barron's says »

BlackRock (BLK),…

BLK

BlackRock

$401.61

1.74 (0.44%)

IVZ

Invesco

$22.00

0.74 (3.48%)

TROW

T. Rowe Price

$100.13

0.31 (0.31%)

SCHW

Charles Schwab

$46.81

0.11 (0.24%)

MTB

M&T Bank

$162.72

2.09 (1.30%)

MS

Morgan Stanley

$46.43

0.4 (0.87%)

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

, BLK

BlackRock

$401.61

1.74 (0.44%)

12:04
10/20/18
10/20
12:04
10/20/18
12:04
Periodicals
Khashoggi case puts financial ties to Saudis under strain, Barron's says »

The suspected killing of…

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

BLK

BlackRock

$401.61

1.74 (0.44%)

BX

Blackstone

$34.66

-0.61 (-1.73%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

IMAX

Imax

$22.45

-0.11 (-0.49%)

SIX

Six Flags

$66.40

-1.16 (-1.72%)

WWE

WWE

$82.02

-1.49 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 13

    Nov

  • 14

    Nov

  • 26

    Feb

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.